These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29568351)

  • 21. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
    Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
    FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
    Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
    Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates.
    Aoyama M; Tada M; Yokoo H; Demizu Y; Ishii-Watabe A
    Pharm Res; 2022 Jan; 39(1):89-103. PubMed ID: 34961908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
    Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
    Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
    Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
    Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC.
    Wu H; Liu C; Yuan Q; Qiao Y; Ding Y; Duan L; Li W; Zhang M; Zhang X; Jiang Y; Lu J; Dong Z; Wang T; Liu K; Zhao J
    Oncoimmunology; 2023; 12(1):2282250. PubMed ID: 38126034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.
    Poźniak M; Porębska N; Krzyścik MA; Sokołowska-Wędzina A; Jastrzębski K; Sochacka M; Szymczyk J; Zakrzewska M; Otlewski J; Opaliński Ł
    Mol Med; 2021 May; 27(1):46. PubMed ID: 33962559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
    Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity.
    Chua JX; Vankemmelbeke M; McIntosh RS; Clarke PA; Moss R; Parsons T; Spendlove I; Zaitoun AM; Madhusudan S; Durrant LG
    Clin Cancer Res; 2015 Jul; 21(13):2963-74. PubMed ID: 25779947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species.
    Glover ZK; Wecksler A; Aryal B; Mehta S; Pegues M; Chan W; Lehtimaki M; Luo A; Sreedhara A; Rao VA
    MAbs; 2022; 14(1):2122957. PubMed ID: 36151884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.
    Niwa R; Shoji-Hosaka E; Sakurada M; Shinkawa T; Uchida K; Nakamura K; Matsushima K; Ueda R; Hanai N; Shitara K
    Cancer Res; 2004 Mar; 64(6):2127-33. PubMed ID: 15026353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
    Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.
    Wirt T; Rosskopf S; Rösner T; Eichholz KM; Kahrs A; Lutz S; Kretschmer A; Valerius T; Klausz K; Otte A; Gramatzki M; Peipp M; Kellner C
    Transfus Med Hemother; 2017 Sep; 44(5):292-300. PubMed ID: 29070974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
    Natsume A; In M; Takamura H; Nakagawa T; Shimizu Y; Kitajima K; Wakitani M; Ohta S; Satoh M; Shitara K; Niwa R
    Cancer Res; 2008 May; 68(10):3863-72. PubMed ID: 18483271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
    Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
    Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A monoclonal antibody against annexin A2 targets stem and progenitor cell fractions in tumors.
    Kalra RS; Soman GS; Parab PB; Mali AM; Varankar SS; Naik RR; Kamble SC; Dhanjal JK; Bapat SA
    Transl Oncol; 2022 Jan; 15(1):101257. PubMed ID: 34715620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies
    Qin H; Wei G; Sakamaki I; Dong Z; Cheng WA; Smith DL; Wen F; Sun H; Kim K; Cha S; Bover L; Neelapu SS; Kwak LW
    Clin Cancer Res; 2018 Mar; 24(5):1114-1123. PubMed ID: 29180606
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.